首页> 外文期刊>RSC Advances >Anti-inflammatory butenolide derivatives from the coral-derived fungus Aspergillus terreus and structure revisions of aspernolides D and G, butyrolactone VI and 4,8-diacetoxy butyrolactone VI
【24h】

Anti-inflammatory butenolide derivatives from the coral-derived fungus Aspergillus terreus and structure revisions of aspernolides D and G, butyrolactone VI and 4,8-diacetoxy butyrolactone VI

机译:来自珊瑚衍生的真菌的抗炎丁烯酯衍生物,曲霉属叶绿素D和G,丁内酯VI和4,8-二乙酰丁内酯VI的结构修订

获取原文
获取原文并翻译 | 示例
           

摘要

Chemical investigation of the coral-derived fungus Aspergillus terreus led to the discovery of ten butenolide derivatives (1-10), including four new ones (1-4). The new structures were characterized on the basis of comprehensive spectroscopic analysis, including 1D and 2D NMR and HRESIMS data. Compounds 1 and 2 were a pair of rare C-8 epimers with vicinal diol motifs. The absolute configurations of 1-4 were determined via [Mo-2(AcO)(4)] induced circular dichroism (ICD) spectra and comparison of their experimental ECD spectra. Importantly, the structures of reported aspernolides D and G, butyrolactone VI and 4,8-diacetoxy butyrolactone VI have been correspondingly revised via a combined strategy of experimental validations, C-13 NMR predictions by ACD/Labs software, and C-13 NMR calculations. Herein we provide valuable referenced C-13 NMR data (C-7, C-8, and C-9) for the structure elucidations of butenolide derivatives with 1-(2-hydroxyphenyl)-3-methylbutane-2,3-diol, 2-(2,3-dihydrobenzofuran-2-yl)propan-2-ol, or 2,2-dimethylchroman-3-ol motifs. Additionally, all the isolates (1-10) were assessed for anti-inflammatory activity by measuring the amount of NO production in lipopolysaccharide (LPS)-induced RAW 264.7 mouse macrophages, and compound 10 showed an even stronger inhibitory effect than the postive control indomethacin, presenting it as a promising lead compound for the development of new anti-inflammatory agents.
机译:珊瑚衍生的真菌的化学研究导致了十种丁醇钠衍生物(1-10)的发现,包括四个新(1-4)。新结构的特征在于综合光谱分析,包括1D和2D NMR和HRESIMS数据。化合物1和2是含有邻甲基二醇基序的一对稀有的C-8个基础。通过[Mo-2(ACO)(4)]诱导的圆形二色性(ICD)光谱和其实验ECD光谱比较确定1-4的绝对配置。重要的是,通过ACD / Labs软件的实验验证C-13 NMR预测和C-13 NMR计算的组合策略,对报告的曲脂糖苷D和G,丁内酯VI和4,8-二乙酰丁内酯VI的结构已相应地修订,C-13 NMR预测和C-13 NMR计算。在此,我们提供有价值的C-13 NMR数据(C-13 NMR数据(C-7,C-8和C-9),用于用1-(2-羟基苯基)-3-甲基丁烷-2,3-二醇的丁醇钠衍生物的结构阐明, 2-(2,3-二氢呋喃脲-2-基)Propan-2-OL,或2,2-二甲基核 - 3-OL主题。另外,通过测量脂多糖(LPS)诱导的未生产的生产量来评估所有分离物(1-10)的抗炎活性,诱导的原料264.7小鼠巨噬细胞,化合物10显示出比垂直控制吲哚美辛的肿瘤效果更强,将其作为开发新的抗炎剂的有前途的铅化合物。

著录项

  • 来源
    《RSC Advances》 |2018年第23期|共8页
  • 作者单位

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Cent Hosp Wuhan Dept Pharm Wuhan 430014 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号